A practical reference on triple agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
The world's longest hot dog had been 60 meters (197 ft) long and rested within a 60.3-meter (198 ft) bun. The hot dog was prepared by Shizuoka Meat Producers for the All-Japan Bread Association, which baked the bun and coordinated the event, including official measurement for the world record. The hot dog and bun were the center of a media event in celebration of the Association's 50th anniversary on August 4, 2006, at the Akasaka Prince Hotel in Tokyo. On May 31, 2012, Guinness World Records certified the world record for the most expensive hot dog at US$145.49. The "California Capitol City Dawg", served at Capitol Dawg in Sacramento, California, features a grilled 460 mm (18 in) all-beef, natural-casing frank from Chicago, served on a fresh-baked herb-and-oil focaccia roll, spread with white truffle butter, then grilled. It is topped with whole-grain mustard from France, garlic and herb mayonnaise, sauteed chopped shallots, organic mixed baby greens, maple syrup-marinated and fruitwood-smoked uncured bacon from New Hampshire, chopped tomato, moose cheese from Sweden, sweetened dried cranberries, basil olive oil and pear-cranberry-coconut balsamic vinaigrette, and ground peppercorn. Proceeds from the sale of each 1.4 kg (3 lb) super dog were donated to the Shriners Hospitals for Children. Hot dogs are a popular food for eating competitions. The record for hot dogs eaten in 10 minutes is 83 by Joey Chestnut at the "Chestnut vs. Kobayashi: Unfinished Beef" event on September 2, 2024. The last person to hold the record before Chestnut was Takeru Kobayashi.
=== Physical and chemical === The physical and chemical properties of the alkali metals can be readily explained by their having an ns1 valence electron configuration, which results in weak metallic bonding. Hence, all the alkali metals are soft and have low densities, melting and boiling points, as well as heats of sublimation, vaporisation, and dissociation. They all crystallise in the body-centered cubic crystal structure, and have distinctive flame colours because their outer s electron is very easily excited. Indeed, these flame test colours are the most common way of identifying them since all their salts with common ions are soluble. The ns1 configuration also results in the alkali metals having very large atomic and ionic radii, as well as very high thermal and electrical conductivity. Their chemistry is dominated by the loss of their lone valence electron in the outermost s-orbital to form the +1 oxidation state, due to the ease of ionising this electron and the very high second ionisation energy. Most of the chemistry has been observed only for the first five members of the group. The chemistry of francium is not well established due to its extreme radioactivity; thus, the presentation of its properties here is limited. What little is known about francium shows that it is very close in behaviour to caesium, as expected. The physical properties of francium are even sketchier because the bulk element has never been observed; hence any data that may be found in the literature are certainly speculative extrapolations.
=== Mice === Mice that produce large amounts of myostatin exhibit a significant loss of skeletal muscle and body fat compared to normal mice. Comparatively, mice that produced decreased levels of myostatin had more muscle mass, less adipose tissue, and were double the size of wild type mice.
Sources: en.wikipedia.org
=== Physical examination === During a physical examination to check for MG, a doctor might ask the person to perform repetitive movements. For instance, the doctor may ask one to look at a fixed point for 30 seconds and to relax the muscles of the forehead, because a person with MG and ptosis of the eyes might be involuntarily using the forehead muscles to compensate for the weakness in the eyelids. The clinical examiner might also try to elicit the "curtain sign" in a person by holding one of the person's eyes open, which in the case of MG will lead the other eye to close.
1993/354) Council Tax (Alteration of Lists and Appeals) (Scotland) Regulations 1993 (S.I. 1993/355) Poultry Laying Flocks (Testing and Registration etc.) (Revocation) Order 1993 (S.I. 1993/357) A249 Trunk Road (M2 to Bobbing Improvement) Order 1993 (S.I. 1993/360) A249 Trunk Road (M2 to Bobbing Improvement Slip Roads) Order 1993 (S.I. 1993/361) A249 Trunk Road (M2 to Bobbing Improvement Detrunking) Order 1993 (S.I. 1993/362) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) A663 Broadway All-Purpose Connecting Road Order 1993 (S.I. 1993/363) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) and Connecting Roads Scheme 1988 Amendment Scheme 1993 (S.I. 1993/364) Local Government Act 1988 (Defined Activities) (Exemption) (Greater Manchester Fire and Civil Defence Authority) Order 1993 (S.I. 1993/365) Local Government Superannuation (Amendment) Regulations 1993 (S.I. 1993/366) Probation (Amendment) Rules 1993 (S.I. 1993/367) Criminal Justice Act 1991 (Contracted Out Prisons) Order 1993 (S.I. 1993/368) Scottish Hospital Trust Scheme 1993 (S.I. 1993/372) Registration of Births, Deaths and Marriages (Fees) (Amendment) Order 1993 (S.I. 1993/377) Cheshire, Lancashire and Merseyside (County Boundaries) Order 1993 (S.I. 1993/378) Norfolk and Suffolk Broads (Extension of Byelaws) Order 1993 (S.I. 1993/379) Defence Research Agency Trading Fund Order 1993 (S.I. 1993/380) Sea Fishing (Enforcement of Community Quota Measures) Order 1993 (S.I. 1993/387) Derbyshire and South Yorkshire (County and District Boundaries) Order 1993 (S.I.
== Sources == Vitamin K1 is primarily from plants, especially leafy green vegetables. Small amounts are provided by animal-sourced foods. Vitamin K2 is primarily from animal-sourced foods, with poultry and eggs much better sources than beef, pork or fish. One exception to the latter is nattō, which is made from bacteria-fermented soybeans. It is a rich food source of vitamin K2 variant MK-7, made by the bacteria.
Sources: en.wikipedia.org
=== Male self-perception === Males may quite easily underestimate the size of their own penis relative to those of others. A survey by sexologists showed that many men who believed that their penis was of inadequate size had average-sized penises. Another study found sex education of standard penile measurements to be helpful and relieving for patients concerned about small penis size, most of whom had incorrect beliefs of what is considered medically normal. The study found that almost all of their patients that were concerned about their penis size overestimated the average penis size. The perception of having a large penis is often linked to higher self-esteem. Fears of shrinking of the penis in folklore have led to a type of mass hysteria called penis panic, though the penis legitimately can shrink in size due to scar tissue formation in the penis from a medical condition called Peyronie's disease. Marketers of penis enlargement products exploit fears of inadequacy, but there is no consensus in the scientific community of any non-surgical technique that permanently increases either the thickness or length of the erect penis that already falls into the normal range. Small penis syndrome (SPS), a term sometimes used in medical literature, is characterized by an obsessive concern that the penis is smaller than average, often despite normal measurements. It has been associated with wider psychological disorders, including anxiety and body dysmorphic disorder. Assessment focuses on confirming normality and addressing underlying psychological factors.
Otherwise, the carbonyl branch is homologous between the two domains and consists of the reduction of another molecule of CO2 to a carbonyl residue bound to an enzyme, catalyzed by the CO dehydrogenase/acetyl-CoA synthase. This key enzyme is also the catalyst for the formation of acetyl-CoA starting from the products of the previous reactions, the methyl and the carbonyl residues. This carbon fixation pathway requires only one molecule of ATP for the production of one molecule of pyruvate, which makes this process one of the main choice for chemolithoautotrophs limited in energy and living in anaerobic conditions.
Carbon nanotubes with amine groups provide numerous chemical sites for carbon dioxide adsorption at low temperature ranges of 20°-100° degrees Celsius. Van der Waals forces and π-π interactions also are used to pull molecules onto surface functional groups. Fullerene can be used to rid of carbon dioxide pollution due to its high adsorption capacity. Graphene nanotubes have functional groups that adsorb gases. There are plenty of nanocatalysts that can be used for air pollution reduction and air quality. Some of these materials include 〖TiO〗_2, Vanadium, Platinum, Palladium, Rhodium, and Silver. Catalytic industrial emission reduction, car exhaust reduction, and air purification are just some of the major thrusts that these nanomaterials are being utilized within. Certain applications are not widely spread, but other are more popular. Indoor air pollution is barely on the market yet, but it is being developed more efficiently due to complications with health effects. Car exhaust emission reduction is widely used in diesel fueled automobiles currently being one of the more popular applications. Industrial emission reduction is also widely used. It is n integral method specifically at coal fired power plants as well as refineries. These methods are analyzed and reviewed using SEM imaging to ensure its usefulness and accuracy. Additionally, research is currently being conducted to find out if nanoparticles can be engineered to separate car exhaust from methane or carbon dioxide, which has been known to damage the Earth's ozone layer.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.